Skip to content
Home/Companies/Biotech/Dorian Therapeutics

Dorian Therapeutics

Biotech·US·Exited 2025·Held 2yr
Entry
2023
Hold
2yr
Exit
2025

Who owns Dorian Therapeutics?

Dorian Therapeutics was owned by Vento through Vento Fund I (2022 vintage) from 2023 to 2025, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-02

Vento
Investor
Vento
Vento Fund I · 2022 · VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2025

More from Vento Fund I

Other portfolio companies in the same fund.

Allelica
Allelica
Active
HealthTechItaly· 2024
Anthropos
Anthropos
Active
HR TechUS· 2024
Arke
Arke
Active
SaaSItaly· 2024
Bee AI
Exited 2025
AI/MLUS· 2024
to
Bland (Bland AI)
Bland (Bland AI)
Active
AI/MLUS· 2024
Cariqa
Cariqa
Active
MobilityGermany· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Dorian Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Dorian Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Dorian Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue